Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Jul;62(7):617–623. doi: 10.1136/ard.62.7.617

Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis

d Forsblad 1, A Larsen 1, E Waltbrand 1, G Kvist 1, D Mellstrom 1, T Saxne 1, C Ohlsson 1, E Nordborg 1, H Carlsten 1
PMCID: PMC1754591  PMID: 12810422

Abstract

Objectives: To investigate determinants of joint destruction and reduced bone mineral density (BMD) in postmenopausal women with active rheumatoid arthritis (RA) not treated with bisphosphonates or hormone replacement therapy and to evaluate if there are common markers of erosive disease and bone loss.

Methods: BMD was measured using dual x ray absorptiometry and joint damage was examined by x ray examination according to the Larsen method in 88 patients with RA. Associations between BMD and Larsen score, and between demographic and disease related variables, including proinflammatory cytokines, HLA-DR4 epitopes, and markers of bone and cartilage turnover, were examined bivariately by simple and multiple linear regression analyses.

Results: 49/88 (56%) patients had osteoporosis in at least one site. Reduced BMD and increased joint destruction were associated with: at the forearm and femoral neck, high Larsen score, low weight, and old age (R2=0.381, p<0.001; R2=0.372, p<0.001, respectively); at the total hip, low weight, high Larsen score, and dose of injected glucocorticosteroids (R2=0.435, p<0.001); at the lumbar spine, low weight, reduced cartilage oligomeric matrix protein, and increased carboxyterminal propeptide of type I procollagen (R2=0.248, p<0.001). Larsen score was associated with long disease duration and increased C reactive protein (CRP) (R2=0.545, p<0.001).

Conclusions: Osteoporosis is common in postmenopausal patients with RA. Low weight and high Larsen score were strongly associated with BMD reduction. Increased CRP and long disease duration were determinants of erosive disease in postmenopausal women with RA. These findings indicate common mechanisms of local and generalised bone loss in RA.

Full Text

The Full Text of this article is available as a PDF (150.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed A. I., Blake G. M., Rymer J. M., Fogelman I. Screening for osteopenia and osteoporosis: do the accepted normal ranges lead to overdiagnosis? Osteoporos Int. 1997;7(5):432–438. doi: 10.1007/s001980050029. [DOI] [PubMed] [Google Scholar]
  2. Arend W. P., Gabay C. Physiologic role of interleukin-1 receptor antagonist. Arthritis Res. 2000 May 19;2(4):245–248. doi: 10.1186/ar94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  4. Cortet B., Flipo R. M., Pigny P., Duquesnoy B., Boersma A., Marchandise X., Delcambre B. Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol. 1998 Dec;25(12):2339–2344. [PubMed] [Google Scholar]
  5. Deodhar A. A., Woolf A. D. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol. 1996 Apr;35(4):309–322. doi: 10.1093/rheumatology/35.4.309. [DOI] [PubMed] [Google Scholar]
  6. Dykman T. R., Gluck O. S., Murphy W. A., Hahn T. J., Hahn B. H. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1985 Apr;28(4):361–368. doi: 10.1002/art.1780280402. [DOI] [PubMed] [Google Scholar]
  7. Ekdahl C., Eberhardt K., Andersson S. I., Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol. 1988;17(4):263–271. doi: 10.3109/03009748809098795. [DOI] [PubMed] [Google Scholar]
  8. Faulkner K. G., Roberts L. A., McClung M. R. Discrepancies in normative data between Lunar and Hologic DXA systems. Osteoporos Int. 1996;6(6):432–436. doi: 10.1007/BF01629574. [DOI] [PubMed] [Google Scholar]
  9. Fex E., Eberhardt K., Saxne T. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Br J Rheumatol. 1997 Nov;36(11):1161–1165. doi: 10.1093/rheumatology/36.11.1161. [DOI] [PubMed] [Google Scholar]
  10. Forslind K., Eberhardt K., Jonsson A., Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol. 1992 Sep;31(9):593–598. doi: 10.1093/rheumatology/31.9.593. [DOI] [PubMed] [Google Scholar]
  11. Fries J. F., Spitz P., Kraines R. G., Holman H. R. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980 Feb;23(2):137–145. doi: 10.1002/art.1780230202. [DOI] [PubMed] [Google Scholar]
  12. Goldring S. R., Gravallese E. M. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 2000 May;12(3):195–199. doi: 10.1097/00002281-200005000-00006. [DOI] [PubMed] [Google Scholar]
  13. Gough A. K., Peel N. F., Eastell R., Holder R. L., Lilley J., Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis. 1994 Jan;53(1):14–17. doi: 10.1136/ard.53.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gough A., Sambrook P., Devlin J., Huissoon A., Njeh C., Robbins S., Nguyen T., Emery P. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol. 1998 Jul;25(7):1282–1289. [PubMed] [Google Scholar]
  15. Gravallese E. M., Manning C., Tsay A., Naito A., Pan C., Amento E., Goldring S. R. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000 Feb;43(2):250–258. doi: 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  16. Hall G. M., Spector T. D., Griffin A. J., Jawad A. S., Hall M. L., Doyle D. V. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum. 1993 Nov;36(11):1510–1516. doi: 10.1002/art.1780361105. [DOI] [PubMed] [Google Scholar]
  17. Haugeberg G., Uhlig T., Falch J. A., Halse J. I., Kvien T. K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000 Mar;43(3):522–530. doi: 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  18. Hooyman J. R., Melton L. J., 3rd, Nelson A. M., O'Fallon W. M., Riggs B. L. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum. 1984 Dec;27(12):1353–1361. doi: 10.1002/art.1780271205. [DOI] [PubMed] [Google Scholar]
  19. Kanis J. A., Melton L. J., 3rd, Christiansen C., Johnston C. C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994 Aug;9(8):1137–1141. doi: 10.1002/jbmr.5650090802. [DOI] [PubMed] [Google Scholar]
  20. Kirwan J. R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995 Jul 20;333(3):142–146. doi: 10.1056/NEJM199507203330302. [DOI] [PubMed] [Google Scholar]
  21. Kröger H., Honkanen R., Saarikoski S., Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study. Ann Rheum Dis. 1994 Jan;53(1):18–23. doi: 10.1136/ard.53.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kröger H., Tuppurainen M., Honkanen R., Alhava E., Saarikoski S. Bone mineral density and risk factors for osteoporosis--a population-based study of 1600 perimenopausal women. Calcif Tissue Int. 1994 Jul;55(1):1–7. doi: 10.1007/BF00310160. [DOI] [PubMed] [Google Scholar]
  23. Laan R. F., van Riel P. L., van Erning L. J., Lemmens J. A., Ruijs S. H., van de Putte L. B. Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol. 1992 Feb;31(2):91–96. doi: 10.1093/rheumatology/31.2.91. [DOI] [PubMed] [Google Scholar]
  24. Laan R. F., van Riel P. L., van de Putte L. B., van Erning L. J., van't Hof M. A., Lemmens J. A. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993 Nov 15;119(10):963–968. doi: 10.7326/0003-4819-119-10-199311150-00001. [DOI] [PubMed] [Google Scholar]
  25. Landin-Wilhelmsen K., Wilhelmsen L., Bengtsson B. A. Postmenopausal osteoporosis is more related to hormonal aberrations than to lifestyle factors. Clin Endocrinol (Oxf) 1999 Oct;51(4):387–394. doi: 10.1046/j.1365-2265.1999.00776.x. [DOI] [PubMed] [Google Scholar]
  26. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol. 1995 Oct;22(10):1974–1975. [PubMed] [Google Scholar]
  27. Lufkin E. G., Wahner H. W., O'Fallon W. M., Hodgson S. F., Kotowicz M. A., Lane A. W., Judd H. L., Caplan R. H., Riggs B. L. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992 Jul 1;117(1):1–9. doi: 10.7326/0003-4819-117-1-1. [DOI] [PubMed] [Google Scholar]
  28. Martin J. C., Munro R., Campbell M. K., Reid D. M. Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol. 1997 Jan;36(1):43–49. doi: 10.1093/rheumatology/36.1.43. [DOI] [PubMed] [Google Scholar]
  29. Michel B. A., Bloch D. A., Wolfe F., Fries J. F. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol. 1993 Oct;20(10):1666–1669. [PubMed] [Google Scholar]
  30. Nepom G. T., Nepom B. S. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum Dis Clin North Am. 1992 Nov;18(4):785–792. [PubMed] [Google Scholar]
  31. Roux S., Orcel P. Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res. 2000 Sep 6;2(6):451–456. doi: 10.1186/ar127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sambrook P. N., Cohen M. L., Eisman J. A., Pocock N. A., Champion G. D., Yeates M. G. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis. 1989 Jul;48(7):535–538. doi: 10.1136/ard.48.7.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sambrook P. N., Eisman J. A., Champion G. D., Yeates M. G., Pocock N. A., Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum. 1987 Jul;30(7):721–728. doi: 10.1002/art.1780300701. [DOI] [PubMed] [Google Scholar]
  34. Sambrook P. N., Spector T. D., Seeman E., Bellamy N., Buchanan R. R., Duffy D. L., Martin N. G., Prince R., Owen E., Silman A. J. Osteoporosis in rheumatoid arthritis. A monozygotic co-twin control study. Arthritis Rheum. 1995 Jun;38(6):806–809. doi: 10.1002/art.1780380614. [DOI] [PubMed] [Google Scholar]
  35. Saxne T., Heinegård D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol. 1992 Sep;31(9):583–591. doi: 10.1093/rheumatology/31.9.583. [DOI] [PubMed] [Google Scholar]
  36. Sinigaglia L., Nervetti A., Mela Q., Bianchi G., Del Puente A., Di Munno O., Frediani B., Cantatore F., Pellerito R., Bartolone S. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000 Nov;27(11):2582–2589. [PubMed] [Google Scholar]
  37. Spector T. D., Hall G. M., McCloskey E. V., Kanis J. A. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ. 1993 Feb 27;306(6877):558–558. doi: 10.1136/bmj.306.6877.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., Koshihara Y., Oda H., Nakamura K., Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000 Feb;43(2):259–269. doi: 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  39. Verstraeten A., Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis. 1986 Oct;45(10):852–857. doi: 10.1136/ard.45.10.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Welsing P. M., van Gestel A. M., Swinkels H. L., Kiemeney L. A., van Riel P. L. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001 Sep;44(9):2009–2017. doi: 10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  41. Weyand C. M., Hicok K. C., Conn D. L., Goronzy J. J. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992 Nov 15;117(10):801–806. doi: 10.7326/0003-4819-117-10-801. [DOI] [PubMed] [Google Scholar]
  42. Wolfe F., Sharp J. T. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum. 1998 Sep;41(9):1571–1582. doi: 10.1002/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  43. Wordsworth P., Pile K. D., Buckely J. D., Lanchbury J. S., Ollier B., Lathrop M., Bell J. I. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet. 1992 Sep;51(3):585–591. [PMC free article] [PubMed] [Google Scholar]
  44. van Everdingen Amalia A., Jacobs Johannes W. G., Siewertsz Van Reesema Dirk R., Bijlsma Johannes W. J. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002 Jan 1;136(1):1–12. doi: 10.7326/0003-4819-136-1-200201010-00006. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES